STEMCELL Technologies Named Company of the Year by BIOTECanada – Business Wire (press release)
|
STEMCELL Technologies Named Company of the Year by BIOTECanada
Business Wire (press release) OTTAWA, Ontario & VANCOUVER, British Columbia–(BUSINESS WIRE)–Vancouver-based biotechnology company STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO … |
The Australian Financial Review |
Mesoblast lining up partners for stem cell trials
Herald Sun Mesoblast’s 30-patient trial found an injection of the company’s MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual … Mesoblast eyes pharma deals after diabetes trial successThe Australian Financial Review Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And …GlobeNewswire (press release) |
The Australian Financial Review |
Mesoblast lining up partners for stem cell trials
The Australian Mesoblast’s 30-patient trial found an injection of the company’s MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual … Mesoblast eyes pharma deals after diabetes trial successThe Australian Financial Review Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And …GlobeNewswire (press release) |
The Australian Financial Review |
Mesoblast lining up partners for stem cell trials
The Australian Mesoblast’s 30-patient trial found an injection of the company’s MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual … Mesoblast eyes pharma deals after diabetes trial successThe Australian Financial Review Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And …GlobeNewswire (press release) |
The Australian Financial Review |
Mesoblast lining up partners for stem cell trials
Business Spectator Mesoblast’s 30-patient trial found an injection of the company’s MPC-300-IV product, an allogeneic mesenchymal precursor cell, was safe and improved organ function. The Melbourne-based company presented the results in poster form at the annual … Mesoblast eyes pharma deals after diabetes trial successThe Australian Financial Review Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And …GlobeNewswire (press release) |
NHL.com |
Howe ‘comfortable’ after stem–cell treatment: report
NHL.com “Our dad continues to participate in a clinical trial where stem cells are being used in the treatment of a stroke,” son Murray Howe told The Hockey News. “We’d like to wait until the first phase of that clinical trial is complete before providing any … |